SMYD2 and central nervous system cancer: As independent confirmation of these data, experiments utilizing the SMYD2 inhibitor, LLY‐507, demonstrated that targeting SMYD2 was effective in inhibiting the proliferation of U373 glioma cells (Figure 6F).